Integrum receives market approval for OPRA[® in Israel]

Mölndal, Sweden – May 29, 2024 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has received market approval for the OPRA® Implant System in Israel.

In March, Integrum entered a commercial agreement with AMI Technologies to Introduce the OPRA® Implant System to the Israeli market. With the market approval in place, AMI Technologies can now start providing OPRA® to hospitals in the region.

"There is a large need for innovative products in the region, and we appreciate the rapid regulatory approval making it possible to soon offer our life-changing treatment to Israeli amputees," says Rickard Brånemark, CEO of Integrum.

This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 29-05-2024 16:22 CET.

For more information, please contact:
Rickard Brånemark, CEO

Phone: +46 (0) 70 846 10 61

Jörgen Svanström, CFO
Phone: + 46 (0) 70 734 96 60

Certified Adviser

Carnegie Investment Bank AB (publ) is Certified Adviser.